CagriSema: Trials and FDA Status
CagriSema is a amylin + glp-1 combination. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Investigational · filed with FDA
- Phase
- Phase 3
- Sponsor
- Novo Nordisk
- Expected FDA decision
- Sponsor statement
- Novo Nordisk states the FDA is expected to review the CagriSema application in 2026 (no decision date given).
- Trial IDs (NCT)
- NCT04982575, NCT05567796, NCT05394519, NCT05669755
Reported results
- 2025REDEFINE 1 phase 3 (NEJM 2025): weight change at 68 weeks vs placebo“The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo”pubmed.ncbi.nlm.nih.gov
- 2 Feb 2026REIMAGINE 2 (type 2 diabetes) headline result, company-reported“CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss”Novo Nordisk (press release)
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
Expected decision: Novo Nordisk states the FDA is expected to review the CagriSema application in 2026 (no decision date given).
- NCT05669755 (REDEFINE 3; Phase 3): primary completion (estimated)
- Novo Nordisk announces REIMAGINE 2 phase 3 headline results
- Published in The lancet. Diabetes & endocrinology (2026): Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- Novo Nordisk announces submission of a New Drug Application to the U.S. FDA for CagriSema
- NCT05394519 (REDEFINE 2; Phase 3): primary completion
- Published in The New England journal of medicine (2025): Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
- Published in The New England journal of medicine (2025): Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
- NCT05567796 (REDEFINE 1; Phase 3): primary completion
- NCT05669755 (REDEFINE 3; Phase 3): study start
- NCT05394519 (REDEFINE 2; Phase 3): study start
- NCT05669755 (REDEFINE 3; Phase 3): first posted on ClinicalTrials.gov
- Published in Lancet (London, England) (2023): Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
- NCT05567796 (REDEFINE 1; Phase 3): study start
- NCT05567796 (REDEFINE 1; Phase 3): first posted on ClinicalTrials.gov
- NCT04982575 (Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes; Phase 2): primary completion
- NCT05394519 (REDEFINE 2; Phase 3): first posted on ClinicalTrials.gov
- NCT04982575 (Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes; Phase 2): study start
- NCT04982575 (Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes; Phase 2): first posted on ClinicalTrials.gov
What the CagriSema registry entries specify
REDEFINE 1 (NCT05567796) tests once-weekly cagrilintide 2.4 mg combined with semaglutide 2.4 mg in people with overweight or obesity, according to its title.[2]
The registry lists 3400 planned participants for REDEFINE 1.[2]
REDEFINE 1 is active, not recruiting: it started 2022-11-01 and reached primary completion on 2024-10-30.[2]
The sponsor's filing release says the REDEFINE 1 programme covered 3,417 adults with obesity or overweight.[9]
REDEFINE 3, the cardiovascular outcomes trial, enrolled 7101 participants.[4]
REDEFINE 3 is active, not recruiting: it started 2023-03-01 and primary completion is estimated for 2027-09-01.[4]
REDEFINE 2, the type 2 diabetes trial, enrolled 1200 participants.[3]
Primary endpoints and trial length
REDEFINE 3's primary endpoint is time to first 3-point major adverse cardiovascular event, a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.[4]
REDEFINE 1's primary outcome includes achieving a weight reduction of at least 5%, for CagriSema versus placebo.[2]
Start to primary completion: REDEFINE 1 104 weeks; REDEFINE 3 235 weeks (est.).
Calculated from NCT05567796 start 2022-11-01, primary completion 2024-10-30, type ACTUAL; NCT05669755 start 2023-03-01, primary completion 2027-09-01, type ESTIMATED. Formula: weeks = round((primary completion date - start date) / 7 days)
Published and sponsor-reported results
In published REDEFINE 1, the estimated change in body weight at week 68 was -20.4% with cagrilintide-semaglutide, against -3.0% with placebo.[6]
For the REIMAGINE 2 diabetes trial, Novo Nordisk reported weight loss of up to 14.2%, with up to 43% of participants reaching 15% or more.[10]
Novo Nordisk reports that discontinuation due to adverse events was 5.9% on CagriSema against 3.5% on placebo in REDEFINE 1, and 8.4% against 3% in REDEFINE 2.[9]
Filing status
Novo Nordisk announced its FDA New Drug Application for once-weekly CagriSema on December 18, 2025.[9]
The release says FDA is expected to review the application in 2026.[9]
Common questions
Is CagriSema FDA approved?
Not as of the sponsor's filing release, which says CagriSema is not approved in the US or EU.[9]
Sources
- 1Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes (NCT04982575)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 2REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (NCT05567796)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 3REDEFINE 2: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (NCT05394519)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 4REDEFINE 3: REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (NCT05669755)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 5Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 2 Oct 2026
- 6Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
- 7Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
- 8Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.The lancet. Diabetes & endocrinology · 2026PMID 42009015Accessed 2 Oct 2026
- 9Novo Nordisk announces submission of a New Drug Application to the U.S. FDA for CagriSemaNovo Nordisk (press release) · 2026Accessed 2 Oct 2026
- 10Novo Nordisk announces REIMAGINE 2 phase 3 headline resultsNovo Nordisk (press release) · 2026Accessed 2 Oct 2026
Found an error? Report a correction.